BR112023016121A2 - Anticorpo triespecífico que direciona bcma, gprc5d e cd3 - Google Patents
Anticorpo triespecífico que direciona bcma, gprc5d e cd3Info
- Publication number
- BR112023016121A2 BR112023016121A2 BR112023016121A BR112023016121A BR112023016121A2 BR 112023016121 A2 BR112023016121 A2 BR 112023016121A2 BR 112023016121 A BR112023016121 A BR 112023016121A BR 112023016121 A BR112023016121 A BR 112023016121A BR 112023016121 A2 BR112023016121 A2 BR 112023016121A2
- Authority
- BR
- Brazil
- Prior art keywords
- antigen
- binding fragments
- antibodies
- multispecific
- bcma
- Prior art date
Links
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 title 1
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 title 1
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 title 1
- 102100021197 G-protein coupled receptor family C group 5 member D Human genes 0.000 title 1
- 101001040713 Homo sapiens G-protein coupled receptor family C group 5 member D Proteins 0.000 title 1
- 230000008685 targeting Effects 0.000 title 1
- 239000000427 antigen Substances 0.000 abstract 10
- 102000036639 antigens Human genes 0.000 abstract 10
- 108091007433 antigens Proteins 0.000 abstract 10
- 239000012634 fragment Substances 0.000 abstract 10
- 101100425747 Mus musculus Tnfrsf17 gene Proteins 0.000 abstract 6
- 238000000034 method Methods 0.000 abstract 2
- 102000040430 polynucleotide Human genes 0.000 abstract 2
- 108091033319 polynucleotide Proteins 0.000 abstract 2
- 239000002157 polynucleotide Substances 0.000 abstract 2
- 239000013598 vector Substances 0.000 abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Abstract
anticorpo triespecífico que direciona bcma, gprc5d e cd3. são aqui fornecidos anticorpos multiespecíficos que se ligam especificamente a bcma, gprc5d e cd3 e fragmentos de ligação ao antígeno multiespecíficos dos mesmos. também são descritos polinucleotídeos relacionados capazes de codificar os anticorpos multiespecíficos ou fragmentos de ligação ao antígeno multiespecíficos fornecidos, células que expressam os anticorpos multiespecíficos ou fragmentos de ligação ao antígeno multiespecíficos fornecidos, assim como vetores associados e anticorpos multiespecíficos ou fragmentos de ligação ao antígeno multiespecíficos detectavelmente marcados. além disso, são descritos métodos de produção e uso dos anticorpos multiespecíficos e fragmentos de ligação ao antígeno fornecidos. são também aqui fornecidos anticorpos que se ligam ao bcma e fragmentos de ligação ao antígeno dos mesmos. são também descritos polinucleotídeos relacionados capazes de codificarem os anticorpos ou fragmentos de ligação ao antígeno específicos para bcma fornecidos, células expressando os anticorpos ou fragmentos de ligação ao antígeno fornecidos, bem como vetores associados e anticorpos específicos para bcma ou fragmentos de ligação ao antígeno detectavelmente marcados. além disso, são descritos métodos de produção e uso dos anticorpos específicos para bcma e fragmentos de ligação ao antígeno fornecidos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163149921P | 2021-02-16 | 2021-02-16 | |
PCT/EP2022/053651 WO2022175255A2 (en) | 2021-02-16 | 2022-02-15 | Trispecific antibody targeting bcma, gprc5d, and cd3 |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112023016121A2 true BR112023016121A2 (pt) | 2023-11-28 |
Family
ID=80445956
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112023016121A BR112023016121A2 (pt) | 2021-02-16 | 2022-02-15 | Anticorpo triespecífico que direciona bcma, gprc5d e cd3 |
Country Status (18)
Country | Link |
---|---|
US (1) | US20220267438A1 (pt) |
EP (1) | EP4294528A2 (pt) |
JP (1) | JP2024507180A (pt) |
KR (1) | KR20230146578A (pt) |
CN (1) | CN117279953A (pt) |
AR (1) | AR124882A1 (pt) |
AU (1) | AU2022221884A1 (pt) |
BR (1) | BR112023016121A2 (pt) |
CA (1) | CA3211163A1 (pt) |
CL (1) | CL2023002382A1 (pt) |
CO (1) | CO2023011907A2 (pt) |
CR (1) | CR20230398A (pt) |
DO (1) | DOP2023000158A (pt) |
EC (1) | ECSP23069904A (pt) |
IL (1) | IL305144A (pt) |
TW (1) | TW202302636A (pt) |
UY (1) | UY39634A (pt) |
WO (1) | WO2022175255A2 (pt) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3911677A1 (en) * | 2019-01-18 | 2021-11-24 | Janssen Biotech, Inc. | Gprc5d chimeric antigen receptors and cells expressing the same |
WO2023236889A1 (zh) * | 2022-06-06 | 2023-12-14 | 山东先声生物制药有限公司 | 靶向bcma、gprc5d和t细胞的多特异性抗体及其应用 |
WO2024050797A1 (zh) * | 2022-09-09 | 2024-03-14 | 北京天广实生物技术股份有限公司 | 结合bcma、gprc5d和cd3的多特异性抗体及其用途 |
WO2024079015A1 (en) * | 2022-10-10 | 2024-04-18 | F. Hoffmann-La Roche Ag | Combination therapy of a gprc5d tcb and imids |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020142000A1 (en) | 1999-01-15 | 2002-10-03 | Digan Mary Ellen | Anti-CD3 immunotoxins and therapeutic uses therefor |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
UA74798C2 (uk) | 1999-10-06 | 2006-02-15 | Байоджен Айдек Ма Інк. | Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами |
WO2001024812A1 (en) | 1999-10-06 | 2001-04-12 | N.V. Nutricia | USE OF TRANSFORMING GROWTH FACTOR β AND GROWTH FACTORS IN THE TREATMENT AND PREVENTION OF DISEASES OF THE INTESTINAL MUCOSA |
JP2004533997A (ja) | 2001-02-20 | 2004-11-11 | ザイモジェネティクス,インコーポレイティド | Bcma及びtaciの両者を結合する抗体 |
MX2007002856A (es) | 2004-09-02 | 2007-09-25 | Genentech Inc | Metodos para el uso de ligandos receptores de muerte y anticuerpos c20. |
EP1870459B1 (en) | 2005-03-31 | 2016-06-29 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing polypeptides by regulating polypeptide association |
DE102005028778A1 (de) | 2005-06-22 | 2006-12-28 | SUNJÜT Deutschland GmbH | Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage |
JP5686953B2 (ja) | 2005-10-11 | 2015-03-18 | アムゲン リサーチ (ミュンヘン) ゲーエムベーハー | 交差種特異的(cross−species−specific)抗体を含む組成物および該組成物の使用 |
KR20080090406A (ko) | 2005-11-28 | 2008-10-08 | 젠맵 에이/에스 | 재조합 1가 항체 및 그의 제조 방법 |
US20090182127A1 (en) | 2006-06-22 | 2009-07-16 | Novo Nordisk A/S | Production of Bispecific Antibodies |
WO2008119566A2 (en) | 2007-04-03 | 2008-10-09 | Micromet Ag | Cross-species-specific bispecific binders |
AU2008234020B2 (en) | 2007-04-03 | 2013-02-07 | Amgen Research (Munich) Gmbh | Cross-species-specific CD3-epsilon binding domain |
ES2432792T5 (es) | 2007-04-03 | 2023-01-16 | Amgen Res Munich Gmbh | Dominio de unión a CD3-épsilon específico de especies cruzadas |
WO2010037838A2 (en) | 2008-10-01 | 2010-04-08 | Micromet Ag | Cross-species-specific single domain bispecific single chain antibody |
KR101820535B1 (ko) | 2008-10-01 | 2018-01-19 | 암젠 리서치 (뮌헨) 게엠베하 | 종간특이적 psmaxcd3 이중특이적 단일쇄 항체 |
HRP20160857T4 (hr) | 2008-10-01 | 2022-12-09 | Amgen Research (Munich) Gmbh | Bispecifična jednolančana protutijela, specifična za visokomolekulske ciljne antigene |
DK2356269T3 (en) | 2008-10-31 | 2016-08-15 | Janssen Biotech Inc | FIBRONECTIN TYPE III DOMAIN-BASED SCAFFOLD COMPOSITIONS, PROCEDURES AND APPLICATIONS |
EP2396011B1 (en) | 2009-02-12 | 2016-04-13 | Janssen Biotech, Inc. | Fibronectin type iii domain based scaffold compositions, methods and uses |
LT2406284T (lt) | 2009-03-10 | 2016-10-10 | Biogen Ma Inc. | Antikūnai prieš b ląstelių subrendimo antigenus |
US9067986B2 (en) | 2009-04-27 | 2015-06-30 | Oncomed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
CN110066339A (zh) | 2010-04-20 | 2019-07-30 | 根马布股份公司 | 含异二聚体抗体fc的蛋白及其制备方法 |
ES2758994T3 (es) | 2010-11-05 | 2020-05-07 | Zymeworks Inc | Diseño anticuerpo heterodimérico estable con mutaciones en el dominio Fc |
CN104080811B (zh) | 2011-11-04 | 2019-09-27 | 酵活有限公司 | 在Fc结构域中具有突变的稳定异源二聚的抗体设计 |
SG11201704552TA (en) | 2014-12-05 | 2017-07-28 | Memorial Sloan Kettering Cancer Center | Antibodies targeting g-protein coupled receptor and methods of use |
PE20180795A1 (es) | 2015-08-17 | 2018-05-09 | Janssen Pharmaceutica Nv | Anticuerpos anti-bcma, moleculas de union a antigenos biespecificas que se unen a bcma y cd3, y uso de estos |
TWI781108B (zh) | 2016-07-20 | 2022-10-21 | 比利時商健生藥品公司 | 抗gprc5d抗體、結合gprc5d與cd3之雙特異性抗原結合分子及其用途 |
BR112019016204A2 (pt) | 2017-02-07 | 2020-07-07 | Daiichi Sankyo Company, Limited | anticorpo ou fragmento de ligação a antígeno do anticorpo, polinucleotídeo, vetor, célula, imunócito artificial, métodos para produzir um anticorpo ou um fragmento de ligação a antígeno do anticorpo, para produzir uma molécula que se liga ao cd3 humano e cd3 de macaco cinomolgo e ao gprc5d humano, composição medicinal para tratamento e/ou prevenção, moléculas tendo atividade de ligação a antígeno e que se ligam ao cd3 humano e cd3 de macaco cinomolgo e ao gprc5d humano, e, usos para preparar um medicamento para tratar e/ou prevenir um câncer, para induzir citotoxicidade para as células expressando gprc5d e para redirecionamento de células t para as células expressando gprc5d |
EP3684816A1 (en) | 2017-09-22 | 2020-07-29 | Kite Pharma, Inc. | Chimeric polypeptides and uses thereof |
TWI829667B (zh) | 2018-02-09 | 2024-01-21 | 瑞士商赫孚孟拉羅股份公司 | 結合gprc5d之抗體 |
SG11202010977QA (en) * | 2018-05-16 | 2020-12-30 | Janssen Biotech Inc | Methods of treating cancers and enhancing efficacy of t cell redirecting therapeutics |
US20200109195A1 (en) * | 2018-05-21 | 2020-04-09 | Compass Therapeutics Llc | Compositions and methods for enhancing the killing of target cells by nk cells |
JOP20190116A1 (ar) | 2018-05-24 | 2019-11-24 | Janssen Biotech Inc | الأجسام المضادة لتكتل التمايز 33 (cd33)، والأجسام المضادة ثنائية النوعية لتكتل التمايز 33 (cd33)/تكتل التمايز 3 (cd3) واستخداماتها |
EP3911677A1 (en) | 2019-01-18 | 2021-11-24 | Janssen Biotech, Inc. | Gprc5d chimeric antigen receptors and cells expressing the same |
US20210284731A1 (en) * | 2020-03-13 | 2021-09-16 | Janssen Biotech, Inc. | Methods and materials for modulating an immune response |
AU2021338776A1 (en) * | 2020-09-11 | 2023-05-25 | Janssen Biotech, Inc. | Multi-specific immune targeting molecules and uses thereof |
KR20230084508A (ko) * | 2020-09-11 | 2023-06-13 | 얀센 바이오테크 인코포레이티드 | 베타 사슬 매개 면역을 조절하기 위한 방법 및 조성물 |
CN112028996B (zh) * | 2020-10-30 | 2021-01-22 | 南京北恒生物科技有限公司 | 靶向bcma的单域抗体及其用途 |
-
2022
- 2022-02-15 AR ARP220100304A patent/AR124882A1/es unknown
- 2022-02-15 IL IL305144A patent/IL305144A/en unknown
- 2022-02-15 AU AU2022221884A patent/AU2022221884A1/en active Pending
- 2022-02-15 WO PCT/EP2022/053651 patent/WO2022175255A2/en active Application Filing
- 2022-02-15 EP EP22705543.1A patent/EP4294528A2/en active Pending
- 2022-02-15 KR KR1020237031153A patent/KR20230146578A/ko unknown
- 2022-02-15 JP JP2023549015A patent/JP2024507180A/ja active Pending
- 2022-02-15 CN CN202280028859.6A patent/CN117279953A/zh active Pending
- 2022-02-15 CR CR20230398A patent/CR20230398A/es unknown
- 2022-02-15 TW TW111105376A patent/TW202302636A/zh unknown
- 2022-02-15 CA CA3211163A patent/CA3211163A1/en active Pending
- 2022-02-15 US US17/672,123 patent/US20220267438A1/en active Pending
- 2022-02-15 BR BR112023016121A patent/BR112023016121A2/pt unknown
- 2022-02-16 UY UY0001039634A patent/UY39634A/es unknown
-
2023
- 2023-08-11 CL CL2023002382A patent/CL2023002382A1/es unknown
- 2023-08-11 DO DO2023000158A patent/DOP2023000158A/es unknown
- 2023-09-07 CO CONC2023/0011907A patent/CO2023011907A2/es unknown
- 2023-09-15 EC ECSENADI202369904A patent/ECSP23069904A/es unknown
Also Published As
Publication number | Publication date |
---|---|
UY39634A (es) | 2022-08-31 |
CR20230398A (es) | 2023-11-15 |
TW202302636A (zh) | 2023-01-16 |
US20220267438A1 (en) | 2022-08-25 |
EP4294528A2 (en) | 2023-12-27 |
AU2022221884A1 (en) | 2023-10-05 |
WO2022175255A3 (en) | 2022-09-29 |
JP2024507180A (ja) | 2024-02-16 |
ECSP23069904A (es) | 2023-10-31 |
CO2023011907A2 (es) | 2023-09-18 |
CL2023002382A1 (es) | 2024-03-15 |
WO2022175255A2 (en) | 2022-08-25 |
DOP2023000158A (es) | 2024-02-29 |
AR124882A1 (es) | 2023-05-17 |
CA3211163A1 (en) | 2022-08-25 |
CN117279953A (zh) | 2023-12-22 |
KR20230146578A (ko) | 2023-10-19 |
IL305144A (en) | 2023-10-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112023016121A2 (pt) | Anticorpo triespecífico que direciona bcma, gprc5d e cd3 | |
CO2017008462A2 (es) | Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123 | |
EA201990781A1 (ru) | Анти-steap2 антитела, конъюгаты антитело-лекарственное средство и биспецифические антигенсвязывающие молекулы, которые связывают steap2 и cd3, и их применение | |
UY37340A (es) | Antianticuerpos gprc5d, moléculas de unión al antígeno biespecíficas que se unen a gprc5d y cd3, y usos de estas | |
CY1123708T1 (el) | Αντισωματα που συνδεονται προς τον ανθρωπινο προσδετη 1 (pd-l1) προγραμματισμενου θανατου | |
PE20180484A1 (es) | Moleculas biespecificas de union a antigeno activadoras de celulas t | |
BR112019005697A2 (pt) | anticorpos anti-muc16-cd3 biespecíficos e conjugados de fármaco e anti-muc16 | |
CO7160115A2 (es) | Proteinas de unión a antigeno que se unen a pd-l1 | |
EA201890785A1 (ru) | Оптимизированные биспецифические анти-cd3 антитела и их применение | |
BR112012023010A2 (pt) | "anticorpo ou fragmento de ligação a antígeno do mesmo que se liga especificamente a cd37, imunoconjugado compreendendo os mesmos, uso dos referidos anticorpo, fragmento e imunoconjugado, composição compreendendo os mesmos, kit, célula isolada, bem como método in vitro para inibir o crescimento de uma célula que expressa cd37" | |
AR077998A1 (es) | Proteinas terapeuticas de union a dll4 | |
NO20073797L (no) | Humane monoklonale antistoffer mot prostata spesifikt membran antigen (PSMA) | |
BR112013027021A2 (pt) | anticorpos anti-igf-1r e anti-erbb3 monoespecíficos e biespecíficos | |
BR112016024214B8 (pt) | Anticorpo monoclonal parcialmente humanizado, composição farmacêutica e uso de um anticorpo monoclonal | |
ZA202201464B (en) | Anti-tigit antibodies and application thereof | |
BR112013009551A2 (pt) | anticorpos | |
BR112021026309A2 (pt) | Anticorpos para ativação de células t | |
BR112023015097A2 (pt) | Proteínas de ligação a psma e usos das mesmas | |
BR112023019484A2 (pt) | Anticorpo triespecífico que tem como alvo cd79b, cd20 e cd3 | |
BR112023002116A2 (pt) | Proteínas que se ligam a nkg2d, cd16 e egfr | |
BR112022021450A2 (pt) | O cd19 ou fragmento de ligação, método de tratamento de um câncer, composição farmacêutica, ácido nucleico, vetor, e, célula isolada | |
UY37915A (es) | Anticuerpos específicos para cd47 y pd-l1 | |
EA202091596A1 (ru) | Антитела к pd-1 и способы лечения | |
EA202092928A1 (ru) | Dll3-cd3 биспецифические антитела | |
MX2023008971A (es) | Materiales y metodos para el seguimiento del cancer mediante la administracion de un anticuerpo anti-mcl1. |